Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed for Chordoma
NCT03955042Phase 1Completed
- Sponsor
- Providence Saint John's Cancer Institute
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemetrexed in chordoma, sponsored by Providence Saint John's Cancer Institute. Primary endpoints: Progression Free Survival at 1 year and Radiographic Response assessed by RECIST v1.1 at 1 year. Started Sep 2019; status: completed.
02
Drugs
pemetrexed
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT03955042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955042.